The Vanderbilt Report logo
  • Home
  • US News
  • World News
  • Finance
    • Company Alerts
    • Current – Previous Alerts
    • US Markets
      • US Charts and Info
      • NASDAQ/NYSE Stocks
      • OTC Stocks
    • Canadian Markets
      • Charts and Info
      • Canadian Markets
  • Cryptocurrency & Blockchain
  • Videos
  • Technology
    • Cybersecurity
    • AI & Machine Learning
    • Energy
  • Additional Pages
    • Health & Medicine
      • Pharmaceutical News
      • Biotechnology
      • General Health
    • Sports
      • Professional Sports
      • College Sports
    • News Room
    • Research Articles
    • Submit Your Article
  • About Vanderbilt
  • Contact Us
  • Sign Up Free
Close
The Vanderbilt Report logo

Menu

  • Home
  • US News
  • World News
  • Finance
    • Company Alerts
    • Current – Previous Alerts
    • US Markets
      • US Charts and Info
      • NASDAQ/NYSE Stocks
      • OTC Stocks
    • Canadian Markets
      • Charts and Info
      • Canadian Markets
  • Cryptocurrency & Blockchain
  • Videos
  • Technology
    • Cybersecurity
    • AI & Machine Learning
    • Energy
  • Additional Pages
    • Health & Medicine
      • Pharmaceutical News
      • Biotechnology
      • General Health
    • Sports
      • Professional Sports
      • College Sports
    • News Room
    • Research Articles
    • Submit Your Article
  • About Vanderbilt
  • Contact Us
  • Sign Up Free

Recent News

Vanderbilt Report: SecureTech’s AI UltraProd Lands Its First U.S. Build Site, Taking Robotic 3D-Printed Housing to California
Company Alerts
November 13, 2026

Vanderbilt Report: SecureTech’s AI UltraProd Lands Its First U.S. Build Site, Taking Robotic 3D-Printed Housing to California

Hepatitis Delta Phase 3 Results: Vir’s Elebsiran and Tobevibart Meet Primary Goal in ECLIPSE 1
Biotechnology Pharmaceutical
November 11, 2026

Hepatitis Delta Phase 3 Results: Vir’s Elebsiran and Tobevibart Meet Primary Goal in ECLIPSE 1

Earlier Bedtime and Weight Loss: NYU Study Links Sleep Timing, Not Sleep Length, to Pounds Lost in Prediabetes
Health
November 11, 2026

Earlier Bedtime and Weight Loss: NYU Study Links Sleep Timing, Not Sleep Length, to Pounds Lost in Prediabetes

COP31 Antalya Opens: Climate Finance Clash, 1.5°C Overshoot Warning and What to Watch as Leaders Arrive
Energy World News
November 10, 2026

COP31 Antalya Opens: Climate Finance Clash, 1.5°C Overshoot Warning and What to Watch as Leaders Arrive

Australia AI Safety Regulator: Albanese Announces Mandatory Safeguards After OpenAI Agent Breached Medicare Portal
AI & Machine Learning Cybersecurity
November 10, 2026

Australia AI Safety Regulator: Albanese Announces Mandatory Safeguards After OpenAI Agent Breached Medicare Portal

  • Home
  • Pharmaceutical
Category : Pharmaceutical
Hepatitis Delta Phase 3 Results: Vir’s Elebsiran and Tobevibart Meet Primary Goal in ECLIPSE 1
Biotechnology Pharmaceutical
November 11, 2026

Hepatitis Delta Phase 3 Results: Vir’s Elebsiran and Tobevibart Meet Primary Goal in ECLIPSE 1

Huntington’s Disease Gene Therapy AMT-130 Gets FDA Priority Review: The Science, the Evidence and What Comes Next
Biotechnology Pharmaceutical
November 4, 2026

Huntington’s Disease Gene Therapy AMT-130 Gets FDA Priority Review: The Science, the Evidence and What Comes Next

Petosemtamab Phase 3 Results: Genmab Head and Neck Cancer Drug Cuts Death Risk 50% With Keytruda
Biotechnology Pharmaceutical
October 29, 2026

Petosemtamab Phase 3 Results: Genmab Head and Neck Cancer Drug Cuts Death Risk 50% With Keytruda

FDA Approves Hibsago: A New Chronic Hepatitis B Treatment Aims for a “Functional Cure”
Biotechnology Pharmaceutical
October 21, 2026

FDA Approves Hibsago: A New Chronic Hepatitis B Treatment Aims for a “Functional Cure”

Admilparant Phase 3 Results: BMS IPF Drug Meets Primary Goal at 60 mg, Misses at 120 mg
Biotechnology Pharmaceutical
October 14, 2026

Admilparant Phase 3 Results: BMS IPF Drug Meets Primary Goal at 60 mg, Misses at 120 mg

Vaxcyte VAX-31 Phase 3 Results: 31-Valent Pneumococcal Vaccine Meets All Primary Endpoints in OPUS-1
Biotechnology Health Pharmaceutical
October 7, 2026

Vaxcyte VAX-31 Phase 3 Results: 31-Valent Pneumococcal Vaccine Meets All Primary Endpoints in OPUS-1

FDA Approves Emcitate, the First MCT8 Deficiency Treatment: The Science, the Evidence and What Comes Next
Biotechnology Pharmaceutical
September 30, 2026

FDA Approves Emcitate, the First MCT8 Deficiency Treatment: The Science, the Evidence and What Comes Next

Viking Therapeutics’ VK2735 Maintenance Data: Less Frequent Dosing Kept Most Weight Off
Biotechnology Editors Picks NYSE-NASDAQ Pharmaceutical
September 23, 2026

Viking Therapeutics’ VK2735 Maintenance Data: Less Frequent Dosing Kept Most Weight Off

Pharmaceutical News Today: FDA Wins, Big M&A, and a New Era of Drug Pricing
Newsroom Pharmaceutical
June 24, 2026

Pharmaceutical News Today: FDA Wins, Big M&A, and a New Era of Drug Pricing

Pharmaceutical News: A Big Month of FDA Decisions and New Drug Firsts
Health Pharmaceutical Top Stories Weekly Recap
June 11, 2026

Pharmaceutical News: A Big Month of FDA Decisions and New Drug Firsts

  • 1
  • 2

Recent Posts

  • Vanderbilt Report: SecureTech’s AI UltraProd Lands Its First U.S. Build Site, Taking Robotic 3D-Printed Housing to California
  • Hepatitis Delta Phase 3 Results: Vir’s Elebsiran and Tobevibart Meet Primary Goal in ECLIPSE 1
  • Earlier Bedtime and Weight Loss: NYU Study Links Sleep Timing, Not Sleep Length, to Pounds Lost in Prediabetes
  • COP31 Antalya Opens: Climate Finance Clash, 1.5°C Overshoot Warning and What to Watch as Leaders Arrive
  • Australia AI Safety Regulator: Albanese Announces Mandatory Safeguards After OpenAI Agent Breached Medicare Portal

Recent Comments

No comments to show.

Popular Posts

Vanderbilt Report: SecureTech’s AI UltraProd Lands Its First U.S. Build Site, Taking Robotic 3D-Printed Housing to California
Company Alerts
November 13, 2026

Vanderbilt Report: SecureTech’s AI UltraProd Lands Its First U.S. Build Site, Taking Robotic 3D-Printed Housing to California

Hepatitis Delta Phase 3 Results: Vir’s Elebsiran and Tobevibart Meet Primary Goal in ECLIPSE 1
Biotechnology Pharmaceutical
November 11, 2026

Hepatitis Delta Phase 3 Results: Vir’s Elebsiran and Tobevibart Meet Primary Goal in ECLIPSE 1

Earlier Bedtime and Weight Loss: NYU Study Links Sleep Timing, Not Sleep Length, to Pounds Lost in Prediabetes
Health
November 11, 2026

Earlier Bedtime and Weight Loss: NYU Study Links Sleep Timing, Not Sleep Length, to Pounds Lost in Prediabetes

COP31 Antalya Opens: Climate Finance Clash, 1.5°C Overshoot Warning and What to Watch as Leaders Arrive
Energy World News
November 10, 2026

COP31 Antalya Opens: Climate Finance Clash, 1.5°C Overshoot Warning and What to Watch as Leaders Arrive

The Vanderbilt Report logo
  • US Markets
  • Canadian Markets
  • Cryptocurrency & Blockchain
  • Company Alerts
  • Technology
  • Health & Medicine
  • Sports
  • Current-Previous Alerts
  • Press Room
  • Research Articles
  • Contact Us
  • About Vanderbilt
  • Submit Your Article
  • Privacy Policy
  • Terms and Conditions
  • Disclaimer


Copyright © VanderBiltReport 2026 | All rights reserved.

WordPress Ads